In recent years, driven by a combination of severe and complex domestic and international factors, China has been undergoing a transition in its growth drivers and an upgrade of its industrial structure. Industrial transformation and upgrading have become one of the most pressing issues as China’s economy enters a new normal.
As a top priority in the development of strategic emerging industries, the biotechnology sector represents a key growth driver for the economy and is now entering a phase of large-scale industrialization. In particular, the early diagnosis of tumors and postoperative screening have become critical issues concerning public health and well-being.
On September 28, 2021, Beijing Xiangxin Biotechnologyand Shenzhen BGI-MGI held an inauguration ceremony for the Demonstration Center for Innovative Applications of High-Throughput Sequencing Technology in the Field of Precision Diagnosis and Treatment of Genitourinary Tumors. The two parties will engage in in-depth cooperation in the field of precision diagnosis and treatment of genitourinary tumors, propelling the biotechnology industry toward a new phase of revolutionary innovation and development.
As a leading enterprise in the genomics sector, Xiangxin Biotechnology operates testing and R&D centers in both Beijing and Tianjin . Notably, Xiangxin Biotechnology’s testing and R&D center in the Wuqing Development Zone of Tianjin was successfully established with the support of Guchuan Lianxing.
Data-Driven Precision Investment Promotion
Transforming "Searching for a Needle in a Haystack" into "Precision Targeting"
Xiangxin Bio is a leading enterprise in China’s precision oncology sector. Since its inception , the company has focused on developing next-generation sequencing (NGS) technologies and building an independently developed genomic big data analysis platform. By integrating technology with this platform, Xiangxin Bio provides clinical settings with precision oncology solutions centered on genomics.
As one of the few NGS medical service companies in the industry leading in both solid and hematological cancers, OakXin Bio has established unique brand advantages in lung cancer, gastrointestinal tumors, urological tumors, and hematological tumors. In 2020, its clinical testing service brand, “Golden Oak Medicine,” completed over 100 million yuan in Series A financing, entering the domestic cancer genetic testing market valued at 10 billion yuan.
After understanding OakBio’s site selection requirements, GuChuan United leveraged its big data platform to quickly identify multiple industrial parks meeting the company’s criteria from a pool of over a hundred options . The firm promptly initiated on-site visits and inspections, conducting comprehensive research on policy incentives, the completeness of the industrial chain, support for startups, and the availability of talent.
Serving as a bridge between the company and the government, GuChuan United accompanied OakXin Biotech throughout its inspection and exchange visits with the Tianjin Wuqing Development Zone, clearing communication barriers for both parties. This ultimately facilitated the company’s establishment in the park and fostered a positive environment for collaborative development between the government and the enterprise.
Seeking Industrial Clusters for Enterprises
Promoting Government-Enterprise Synergy for Mutual Prosperity
Located in the heart of the Beijing-Tianjin corridor, the Tianjin Wuqing Development Zone boasts a uniquely advantageous geographical position. Over the years ,the zone has attracted total investments exceeding 40 billion yuanandwelcomed nearly 1,000 enterprises,including14 Fortune 500 companies, forming three major industrial clusters centered on high-end equipment manufacturing, life sciences and healthcare, and modern services.
A complete industrial chain is crucial for the long-term development of biopharmaceutical enterprises. It not only facilitates the sharing of quality inspection resources and preferential policies, as well as the joint construction of public service platforms, but also further strengthens regional development advantages and creates a brand effect.
Currently, the Tianjin Wuqing Development Zone is home to over 160 biopharmaceutical enterprises and has established a dedicated biopharmaceutical industry fund, primarily targeting early-to-mid-stage high-end R&D projects in the sector—whether already established or planning to establish operations there . Comprehensive industrial development support policies were also a key factor in Xiangxin Biotech’s decision to ultimately locate in the Tianjin Wuqing Development Zone.
Technological innovation in China’s biopharmaceutical sector is gradually aligning with global standards. With the dual impetus of government policy support and the rapid advancement of digital technology, the future outlook for biopharmaceutical industries similar to Xiangxin Bio is expected to be highly promising.
With 12 years of deep expertise in investment promotion , GuChuan United has accumulated over 550,000 project resources and successfully established a big data platform integrating vast project and host facility resources. Building on this foundation, GuChuan United is able to rapidly analyze information from all angles and multiple dimensions to assess corporate growth potential and evaluate the comprehensive strengths of industrial parks.
Moving forward, Guchuan United will continue to drive targeted investment promotion through data-driven approaches, deeply exploring the genuine needs of enterprises, governments, and industrial parks. By integrating these insights with the region’s existing industrial foundations and strengths, we will precisely attract industries and comprehensively advance the prosperous development of the regional economy.
